A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (CBD Technosphere Inhalation Powder) in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Anxiety; Social phobia
Focus Adverse reactions; Proof of concept
Sponsors Receptor Life Sciences

Most Recent Events

29 Mar 2024 Status changed to withdrawn prior to enrolment due to lack of enrollment.
26 Apr 2023 Status changed from recruiting to completed.
29 Jun 2022 According to a Receptor Life Sciences media release, first patient has been dosed in this study and company expects to report topline results of this study by early 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight